Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

Natriuretic Peptide (ANP)vsThymosin Beta-4

Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

Healing & RecoveryHealing & Recovery

At a Glance

Quick
comparison

Dose Range

Natriuretic Peptide (ANP)

As prescribed–As prescribed mg

Thymosin Beta-4

2–5 mg

Frequency

Natriuretic Peptide (ANP)

Once daily

Thymosin Beta-4

Twice weekly

Administration

Natriuretic Peptide (ANP)

Intravenous infusion (continuous) - standard hospital delivery method

Thymosin Beta-4

Subcutaneous injection

Cycle Length

Natriuretic Peptide (ANP)

Ongoing/indefinite

Thymosin Beta-4

8-12 weeks

Onset Speed

Natriuretic Peptide (ANP)

Moderate (1-2 weeks)

Thymosin Beta-4

Moderate (1-2 weeks)

Evidence Level

Natriuretic Peptide (ANP)

Moderate human trials (Phase 1-2)

Thymosin Beta-4

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Natriuretic Peptide (ANP)
Thymosin Beta-4

Acute Fluid Management

Natriuretic Peptide (ANP)82%
Thymosin Beta-40%

Hemodynamic Stabilization

Natriuretic Peptide (ANP)78%
Thymosin Beta-40%

Symptom Relief

Natriuretic Peptide (ANP)74%
Thymosin Beta-40%

Wound Healing

Natriuretic Peptide (ANP)0%
Thymosin Beta-495%

Inflammation Reduction

Natriuretic Peptide (ANP)0%
Thymosin Beta-488%

Tissue Regeneration

Natriuretic Peptide (ANP)0%
Thymosin Beta-492%

Technical Data

Compound
specifications

Natriuretic Peptide (ANP)

Molecular Formula

C127H203N45O39S3

Molecular Weight

3080.5 g/mol

Half-Life

Approximately 15-30 minutes (IV administration)

Bioavailability

100% (intravenous administration)

CAS Number

Variable depending on salt form; carperitide CAS: 120399-20-4

Thymosin Beta-4

Molecular Formula

C212H350N56O78S

Molecular Weight

4963

Half-Life

Dose-dependent (increases with higher doses)

Bioavailability

100% (subcutaneous and intravenous)

CAS Number

77591-33-4

Applications

Best
suited for

Natriuretic Peptide (ANP)

Managing acute decompensated heart failure with fluid overload

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving shortness of breath caused by pulmonary congestion

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Lowering elevated blood pressure in emergency cardiac situations

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing the workload on the heart during acute episodes

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery

Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring

Chronic Wound Management

Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster

Tissue Regeneration

Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety Profile

Side
effects

Natriuretic Peptide (ANP)

Common

  • Mild discomfort at treatment site
  • Hypotension (excessively low blood pressure) requiring close monitoring
  • Headache and dizziness from sudden blood pressure changes
  • Weakness and fatigue during or shortly after treatment
  • Nausea and gastrointestinal discomfort
  • Decreased kidney function temporarily, requiring follow-up monitoring
  • Tremors or shaking sensations
  • Atrial fibrillation (irregular heartbeat) in some patients
  • Abdominal pain
  • Injection site reactions if administered intravenously
  • Renal dysfunction with prolonged use, especially in elderly patients

Serious

  • Severe allergic reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Natriuretic Peptide (ANP)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion requires periodic treatment breaks or dose adjustments.

Contraindications

  • xSevere kidney failure with very low glomerular filtration rate
  • xRecent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
  • xAcute coronary syndrome or recent heart attack where vasodilation could be harmful
  • xSevere hypotension or cardiogenic shock without proper supportive care
  • xAllergies to ANP, carperitide, or any components of the pharmaceutical formulation

Thymosin Beta-4

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • xActive systemic infections
  • xSevere immunosuppression
  • xHypersensitivity to thymosin or any component
  • xPregnancy (insufficient safety data)

Decision Guide

Which is
right for you?

Choose Natriuretic Peptide (ANP) if...

  • Managing acute decompensated heart failure with fluid overload
  • Relieving shortness of breath caused by pulmonary congestion
  • Lowering elevated blood pressure in emergency cardiac situations
  • Reducing the workload on the heart during acute episodes

Choose Thymosin Beta-4 if...

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation